These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33923431)

  • 61. Endoplasmic Reticulum Stress and Ca2+ Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism.
    Lebeau P; Al-Hashimi A; Sood S; Lhoták Š; Yu P; Gyulay G; Paré G; Chen SR; Trigatti B; Prat A; Seidah NG; Austin RC
    J Biol Chem; 2017 Jan; 292(4):1510-1523. PubMed ID: 27909053
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
    Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
    Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.
    Romagnuolo R; Scipione CA; Marcovina SM; Gemin M; Seidah NG; Boffa MB; Koschinsky ML
    PLoS One; 2017; 12(7):e0180869. PubMed ID: 28750079
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A Therapeutic Peptide Vaccine Against PCSK9.
    Pan Y; Zhou Y; Wu H; Chen X; Hu X; Zhang H; Zhou Z; Qiu Z; Liao Y
    Sci Rep; 2017 Oct; 7(1):12534. PubMed ID: 28970592
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease.
    Cao G; Qian YW; Kowala MC; Konrad RJ
    Endocr Metab Immune Disord Drug Targets; 2008 Dec; 8(4):238-43. PubMed ID: 19075777
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2.
    Jeong HJ; Lee HS; Kim KS; Kim YK; Yoon D; Park SW
    J Lipid Res; 2008 Feb; 49(2):399-409. PubMed ID: 17921436
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Fibrillar collagen inhibits cholesterol biosynthesis in human aortic smooth muscle cells.
    Ferri N; Roncalli E; Arnaboldi L; Fenu S; Andrukhova O; Aharinejad S; Camera M; Tremoli E; Corsini A
    Arterioscler Thromb Vasc Biol; 2009 Oct; 29(10):1631-7. PubMed ID: 19608976
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway.
    Li X; Hu X; Pan T; Dong L; Ding L; Wang Z; Song R; Wang X; Wang N; Zhang Y; Wang J; Yang B
    Biomed Pharmacother; 2021 Jan; 133():110802. PubMed ID: 33202286
    [TBL] [Abstract][Full Text] [Related]  

  • 69. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
    Roglans N; Verd JC; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
    Lipids; 2002 May; 37(5):445-54. PubMed ID: 12056585
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
    Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW
    Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945
    [TBL] [Abstract][Full Text] [Related]  

  • 71. T-cadherin promotes vascular smooth muscle cell dedifferentiation via a GSK3β-inactivation dependent mechanism.
    Frismantiene A; Dasen B; Pfaff D; Erne P; Resink TJ; Philippova M
    Cell Signal; 2016 May; 28(5):516-530. PubMed ID: 26907733
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Corsini A; Bernini F; Quarato P; Donetti E; Bellosta S; Fumagalli R; Paoletti R; Soma VM
    Cardiology; 1996; 87(6):458-68. PubMed ID: 8904671
    [TBL] [Abstract][Full Text] [Related]  

  • 73. PCSK9 induces a pro-inflammatory response in macrophages.
    Ricci C; Ruscica M; Camera M; Rossetti L; Macchi C; Colciago A; Zanotti I; Lupo MG; Adorni MP; Cicero AFG; Fogacci F; Corsini A; Ferri N
    Sci Rep; 2018 Feb; 8(1):2267. PubMed ID: 29396513
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intimal smooth muscle cells of porcine and human coronary artery express S100A4, a marker of the rhomboid phenotype in vitro.
    Brisset AC; Hao H; Camenzind E; Bacchetta M; Geinoz A; Sanchez JC; Chaponnier C; Gabbiani G; Bochaton-Piallat ML
    Circ Res; 2007 Apr; 100(7):1055-62. PubMed ID: 17347479
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).
    Ben Djoudi Ouadda A; Gauthier MS; Susan-Resiga D; Girard E; Essalmani R; Black M; Marcinkiewicz J; Forget D; Hamelin J; Evagelidis A; Ly K; Day R; Galarneau L; Corbin F; Coulombe B; Çaku A; Tagliabracci VS; Seidah NG
    Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):1996-2013. PubMed ID: 31553664
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Phaleria macrocarpa (Scheff.) Boerl fruit aqueous extract enhances LDL receptor and PCSK9 expression in vivo and in vitro.
    Chong SC; Dollah MA; Chong PP; Maha A
    J Ethnopharmacol; 2011 Sep; 137(1):817-27. PubMed ID: 21763412
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis.
    Lu X
    Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
    Turner NA; Midgley L; O'Regan DJ; Porter KE
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):458-61. PubMed ID: 18049315
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].
    Pedro-Botet J; Badimón L
    Clin Investig Arterioscler; 2016 May; 28 Suppl 2():3-8. PubMed ID: 27888903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.